Medicines containing levamisole will be withdrawn from the European market. The decision comes from the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), following a safety review that found that the benefit-risk balance is no longer favorable.
Why the EMA Ordered the Withdrawal of Levamisole
The PRAC (Pharmacovigilance Risk Assessment Committee), the EMA body responsible for the safety of medicines in the European Union, has recommended the withdrawal of all medicines containing levamisole.
After an in-depth analysis of the available data, experts concluded that the therapeutic benefits